参考文献/References:
[1] Ajala ON,Everett BM. Targeting inflammation to reduce residual cardiovascular risk[J]. Curr Atheroscler Rep,2020,22(11):66.
[2] Olsen AM,Fosb?l EL,Lindhardsen J,et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction:a nationwide cohort study[J]. Circulation,2012,126(16):1955-1963.
[3] Vogel RA,Forrester JS. Cooling off hot hearts:a specific therapy for vulnerable plaque[J]. J Am Coll Cardiol,2013,61(4):411-412.
[4] Ridker PM,Everett BM,Pradhan A,et al. Low-dose methotrexate for the prevention of atherosclerotic events[J]. N Engl J Med,2019,380(8):752-762.
[5] Klingenberg R,Lüscher TF. CANTOS:a seductive song with several verses[J]. Eur Heart J,2018,39(38):3508-3510.
[6] van Hout GP,Bosch L,Ellenbroek GH,et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction[J]. Eur Heart J,2017,38(11):828-836.
[7] Parisi V,Petraglia L,D’Esposito V,et al. Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue[J]. Int J Cardiol,2019,274:326-330.
[8] Opstal T,Hoogeveen RM,Fiolet A,et al. Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease:A LoDoCo2 Proteomic Substudy[J]. Circulation,2020,142(20):1996-1998.
[9] Martínez GJ,Celermajer DS,Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation[J]. Atherosclerosis,2018,269:262-271.
[10] Shah B,Allen N,Harchandani B,et al. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions:a pilot study in healthy subjects[J]. Inflammation,2016,39(1):182-189.
[11] Barraclough JY,Joglekar MV,Januszewski AS,et al. A microRNA signature in acute coronary syndrome patients and modulation by colchicine[J]. J Cardiovasc Pharmacol Ther,2020,25(5):444-455.
[12] Jong WM,Leemans JC,Weber NC,et al. Nlrp3 plays no role in acute cardiac infarction due to low cardiac expression[J]. Int J Cardiol,2014,177(1):41-43.
[13] He Y,Zeng MY,Yang D,et al. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux[J]. Nature,2016,530(7590):354-357.
[14] Solomon DH,Liu CC,Kuo IH,et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout:a cohort study using electronic medical records linked with Medicare claims[J]. Ann Rheum Dis,2016,75(9):1674-1679.
[15] Fiolet A,Silvis M,Opstal T,et al. Short-term effect of low-dose colchicine on inflammatory biomarkers,lipids,blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein[J]. PLoS One,2020,15(8):e0237665.
[16] Nidorf M,Thompson PL. Effect of colchicine(0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease[J]. Am J Cardiol,2007,99(6):805-807.
[17] Nidorf SM,Eikelboom JW,Budgeon CA,et al. Low-dose colchicine for secondary prevention of cardiovascular disease[J]. J Am Coll Cardiol,2013,61(4):404-410.
[18] Nidorf SM,Fiolet A,Mosterd A,et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med,2020,383(19):1838-1847.
[19] Xia M,Yang X,Qian C. Meta-analysis evaluating the utility of colchicine in secondary prevention of coronary artery disease[J]. Am J Cardiol,2021,140:33-38.
[20] Tien YY,Huang HK,Shih MC,et al. Drug repurposing? Cardiovascular effect of colchicine on patients with coronary artery disease:a systematic review and meta-analysis[J]. J Cardiol,2021,77(6):576-582.
[21] Mani P,Puri R,Schwartz GG,et al. Association of initial and serial C-reactive protein levels with adverse cardiovascular events and death after acute coronary syndrome:a secondary analysis of the VISTA-16 trial[J]. JAMA Cardiol,2019,4(4):314-320.
[22] Vaidya K,Arnott C,Martínez GJ,et al. Colchicine therapy and plaque stabilization in patients with acute?coronary syndrome:a CT coronary angiography study[J]. JACC Cardiovasc Imaging,2018,11(2 Pt 2):305-316.
[23] Deftereos S,Giannopoulos G,Angelidis C,et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction:a pilot study[J]. Circulation,2015,132(15):1395-1403.
[24] Tardif JC,Kouz S,Waters DD,et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med,2019,381(26):2497-2505.
[25] Akodad M,Fauconnier J,Sicard P,et al. Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model[J]. Int J Cardiol,2017,240:347-353.
[26] Fujisue K,Sugamura K,Kurokawa H,et al. Colchicine improves survival,left ventricular remodeling,and chronic cardiac function after acute myocardial infarction[J]. Circ J,2017,81(8):1174-1182.
[27] Kajikawa M,Higashi Y,Tomiyama H,et al. Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease[J]. Int J Cardiol,2019,281:35-39.
[28] Guedeney P,Claessen BE,Kalkman DN,et al. Residual inflammatory risk in patients?with low LDL cholesterol levels?undergoing percutaneous coronary?intervention[J]. J Am Coll Cardiol,2019,73(19):2401-2409.
[29] Martínez GJ,Robertson S,Barraclough J,et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome[J]. J Am Heart Assoc,2015,4(8):e002128.
[30] Shah B,Pillinger M,Zhong H,et al. Effects of acute colchicine administration prior to percutaneous coronary intervention:COLCHICINE-PCI Randomized Trial[J]. Circ Cardiovasc Interv,2020,13(4):e008717.
[31] O’Keefe JH Jr,McCallister BD,Bateman TM,et al. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty[J]. J Am Coll Cardiol,1992,19(7):1597-1600.
[32] Deftereos S,Giannopoulos G,Raisakis K,et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients[J]. J Am Coll Cardiol,2013,61(16):1679-1685.
[33] Tong DC,Quinn S,Nasis A,et al. Colchicine in patients with acute coronary syndrome:The Australian COPS Randomized Clinical Trial[J]. Circulation,2020,142(20):1890-1900.
[34] Stewart S,Yang K,Atkins K,et al. Adverse events during oral colchicine use:a systematic review and meta-analysis of randomised controlled trials[J]. Arthritis Res Ther,2020,22(1):28.
[35] Cirillo P,Taglialatela V,Pellegrino G,et al. Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel[J]. J Thromb Thrombolysis,2020,50(2):468-472.
[36] Sag E,Bayindir Y,Adiguzel A,et al. Colchicine and leukopenia:clinical implications[J]. J Pediatr,2020,224:166-170.e1.
[37] Baker SK,Goodwin S,Sur M,et al. Cytoskeletal myotoxicity from simvastatin and colchicine[J]. Muscle Nerve,2004,30(6):799-802.
[38] Huang C,Cen C,Wang C,et al. Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia[J]. Lipids Health Dis,2014,13:67.
[39] Hennessy T,Soh L,Bowman M,et al. The Low Dose Colchicine after Myocardial Infarction(LoDoCo-MI) study:a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction[J]. Am Heart J,2019,215:62-69.
[40] Hemkens LG,Ewald H,Gloy VL,et al. Colchicine for prevention of cardiovascular events[J]. Cochrane Database Syst Rev,2016,2016(1):CD011047.
[41] McKnight AH,Katzenberger DR,Britnell SR. Colchicine in acute coronary syndrome:a systematic review[J]. Ann Pharmacother,2021,55(2):187-197.
相似文献/References:
[1]胥雪莲,何川.炎症与动脉粥样硬化[J].心血管病学进展,2015,(5):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
XU Xuelian,HE Chuan.Inflammation and Atherosclerosis[J].Advances in Cardiovascular Diseases,2015,(1):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
[2]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(1):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[3]赵丹 周鹏.达比加群及其逆转剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
ZHAO DanZHOU Peng.Dabigatran and Reversal in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
[4]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[5]陈元 楚天舒 武力勇.瘦素抵抗、瘦素受体基因多态性与冠状动脉粥样硬化性心脏病的相关性进展[J].心血管病学进展,2019,(8):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
CHEN Yuan,CHU Tianshu,WU Liyong.Leptin Resistance,Leptin Receptor Gene Polymorphism and Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
[6]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[7]宋志平 杨永健.GPR 35在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
SONG Zhiping,YANG Yongjian.The Current Progress of GPR 35 in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
[8]顾佳仪 刘正霞 鲁翔.白介素-1β在冠心病中的研究进展[J].心血管病学进展,2020,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.006]
Gu Jiayi,Liu Zhengxia,Lu Xiang.Interleukin-1 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(1):125.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.006]
[9]王辉 蒋永兴 田野.下肢动脉硬化闭塞症：炎症机制与抗炎治疗的研究进展[J].心血管病学进展,2020,(2):179.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.020]
WANG HuiJIANG YongxingTIAN Ye.Peripheral Arterial DiseaseA Research Progress Review of Inflammatory Mechanism and Anti-inflammatory Therapy[J].Advances in Cardiovascular Diseases,2020,(1):179.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.020]
[10]严宁,杨春霞,马娟,等.β-谷甾醇对大鼠心肌缺血再灌注损伤和ERK1/2信号通路的影响[J].心血管病学进展,2020,(3):321.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.026]
YAN Ning,YANG Chunxia,MA Juan,et al.Effects of -sitosterolon Myocardial Ischemia-reperfusion Injury and ERK1/2 Signaling Pathway in Rats[J].Advances in Cardiovascular Diseases,2020,(1):321.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.026]
[11]曾祥烨 王蔚宗 周桐羽 杜晓诗 孟庆欣 李丙松 高梅.冠状动脉扩张症：非冠状动脉粥样硬化性心脏病的特殊类型[J].心血管病学进展,2024,(10):902.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.008]
ZENG Xiangye,WANG Weizong,ZHOU Tongyu,et al.Coronary Artery Ectasia:A Specialized Type of Non-Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2024,(1):902.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.008]